Global Veterinary Biologics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Veterinary Biologics Market: By Product Type (Vaccines, Diagnostic Kits, Antibody Products, Others), By Disease (Bluetongue, Aujeszky’s Disease, Bovine Viral Diarrhea, Bovine Tuberculosis, Clostridial Disease, Foot and Mouth Disease, Others), By Species (Poultry, Bovine, Aquatic, Porcine, Others), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Veterinary Biologics Market size was valued at USD 11.2 billion in 2021, growing at a CAGR of 7.1% during the forecast period 2022-28 . Global veterinary biologics market is primarily driven by increase in demand for food security around the world and initiatives by the various government and non-government organizations to vaccinate the animals. The veterinary biologics industry is currently highly concentrated, with prominent firms such as Zoetis, Boehringer Ingelheim, Ceva, Elanco Animal Health, and Merck Animal Health accounting for two-thirds of the revenue share. These companies are increasingly delegating their innovation to startups and other collaborators with superior genomics and biotech knowledge. Furthermore, increasing investments in veterinary science and multi-disciplinary vaccinology research are projected to propel the veterinary biologics market to new heights. In light of growing livestock production and booming pet product sales, a major transformation in the animal health business will further create a window of growth potential. The growing number of veterinary clinics in both developed and emerging countries, which account for 2/5 of total revenue, is driving demand for veterinary biologics. Market participants are directing their product sales through retail pharmacies in order to boost their profit margins and regional presence. Increased government emphasis on the unification of research in veterinary pharmaceuticals and human medicine can also be attributable to significant rise in veterinary biologics sales through these channels. However, a major gap in understanding the epidemiology pattern of animal diseases remains a potential hazard to market participants. As illnesses evolve, vaccination research and development has been ramped up to protect animals from new strains. Veterinary biologics, such as monoclonal antibodies and immunomodulators, will also see advancements.

Veterinary Biologics Market

MARKET SUMMARY
-
7.1%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 7.1%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Veterinary Biologics Market

  • The report on global Veterinary Biologics Market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, disease, species and geography.
  • Veterinary Biologics Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Zoetis, Inc. (U.S.)
  • ElancoAnimal Health (Eli Lilly and Company) (U.S.)
  • Merial (C.H. BoehringerSohn AG & Co. KG) (Germany)
  • Merck & Co., Inc. (U.S.)
  • Bayer AG (Germany)
Veterinary Biologics Market Dynamics

Growing demand for meat and rise in trend towards adaptation of companion animals in developing countries projected to boost the market share. Moreover, increase in company investments to produce advanced and novel veterinary biologics coupled with growing animal health concerns expected to bolster the global veterinary biologics market. However, lack of knowledge in some of the virulent veterinary diseases and regulatory procedures are expected to impede the global market over the forecast period


North-America Got Significant Share

Veterinary Biologics Market

Geographically veterinary biologics market is divided into five key regions, i.e. North America, Europe, AsiaPacific, Latin America, and the Middle East and Africa. North America veterinary biologics market is driven by the presence of key market players, increase in R&D expenditure by the companies on veterinary biologics, especially development of vaccines. Furthermore, bio pharma companies are expanding its business to animal health by establishing the new divisions. For instance, IDT Biologika, a German headquartered company has established a new animal health organization in America, IDT Animal Health Americas to offer a range of wildlife, autogenous, and commercial vaccines and diagnostic solutions for animal use. Asia Pacific veterinary biologics market is projected to grow at significant rates owing to increase in disease awareness and growing health concerns. Furthermore, company exposition to the Asian emerging countries to strengthen their global market share projected to boost the Asia pacific biologics market. Europe veterinary biologics market expected to have significant growth rate owing to the government initiatives on vaccination of animals and growing animal health concerns

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenari0
Veterinary Biologics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Zoetis, Inc. (U.S.)
  • ElancoAnimal Health (Eli Lilly and Company) (U.S.)
  • Merial (C.H. BoehringerSohn AG & Co. KG) (Germany)
  • Merck & Co., Inc. (U.S.)
  • Bayer AG (Germany)
  • CevaSanteAnimale S.A. (France)
  • Virbac (France)

Description

Veterinary Biologics Market size was valued at USD 11.2 billion in 2021, growing at a CAGR of 7.1% during the forecast period 2022-28 . Global veterinary biologics market is primarily driven by increase in demand for food security around the world and initiatives by the various government and non-government organizations to vaccinate the animals. The veterinary biologics industry is currently highly concentrated, with prominent firms such as Zoetis, Boehringer Ingelheim, Ceva, Elanco Animal Health, and Merck Animal Health accounting for two-thirds of the revenue share. These companies are increasingly delegating their innovation to startups and other collaborators with superior genomics and biotech knowledge. Furthermore, increasing investments in veterinary science and multi-disciplinary vaccinology research are projected to propel the veterinary biologics market to new heights. In light of growing livestock production and booming pet product sales, a major transformation in the animal health business will further create a window of growth potential. The growing number of veterinary clinics in both developed and emerging countries, which account for 2/5 of total revenue, is driving demand for veterinary biologics. Market participants are directing their product sales through retail pharmacies in order to boost their profit margins and regional presence. Increased government emphasis on the unification of research in veterinary pharmaceuticals and human medicine can also be attributable to significant rise in veterinary biologics sales through these channels. However, a major gap in understanding the epidemiology pattern of animal diseases remains a potential hazard to market participants. As illnesses evolve, vaccination research and development has been ramped up to protect animals from new strains. Veterinary biologics, such as monoclonal antibodies and immunomodulators, will also see advancements.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX